The stock of Kala Pharmaceuticals, Inc. (NASDAQ:KALA) is a huge mover today! The stock increased 2.54% or $0.34 during the last trading session, reaching $13.72. About 102,519 shares traded. Kala Pharmaceuticals, Inc. (NASDAQ:KALA) has 0.00% since June 12, 2017 and is . It has underperformed by 12.57% the S&P500. Some Historical KALA News: ; 12/03/2018 – REG-Neste Corporation – Nofication of Managers’ Transactions, Mäki-Kala; 10/05/2018 – Kala Pharmaceuticals 1Q Loss/Shr 46c; 12/03/2018 Neste Oil: Neste Corporation – Nofication of Managers’ Transactions, Mäki-Kala; 26/03/2018 – KALA PHARMACEUTICALS INC – PDUFA TARGET ACTION DATE FOR INVELTYS IS AUGUST 24, 2018; 26/03/2018 – Kala Pharmaceuticals 4Q Loss $11.3M; 14/05/2018 – Brown Advisory Buys New 1% Position in Kala Pharmaceuticals; 26/03/2018 – Kala Pharmaceuticals 4Q Loss/Shr 46c; 10/05/2018 – Kala Pharmaceuticals 1Q Loss $11.3M; 03/04/2018 – KALA PHARMACEUTICALS APPOINTS ERIC TRACHTENBERG AS GENERAL COUNSEL AND CORPORATE SECRETARY; 03/04/2018 – KALA PHARMACEUTICALS NAMES ERIC TRACHTENBERG AS GENERAL COUNSELThe move comes after 7 months positive chart setup for the $337.00 million company. It was reported on Jun, 12 by Barchart.com. We have $14.54 PT which if reached, will make NASDAQ:KALA worth $20.22 million more.
Albireo Pharma Inc (NASDAQ:ALBO) had an increase of 156.56% in short interest. ALBO’s SI was 132,900 shares in June as released by FINRA. Its up 156.56% from 51,800 shares previously. With 74,900 avg volume, 2 days are for Albireo Pharma Inc (NASDAQ:ALBO)’s short sellers to cover ALBO’s short positions. The SI to Albireo Pharma Inc’s float is 3.75%. The stock decreased 1.84% or $0.6 during the last trading session, reaching $32.01. About 104,397 shares traded or 78.47% up from the average. Albireo Pharma, Inc. (NASDAQ:ALBO) has risen 70.38% since June 12, 2017 and is uptrending. It has outperformed by 57.81% the S&P500. Some Historical ALBO News: ; 14/05/2018 – Tekla Capital Buys New 1% Position in Albireo Pharma; 17/05/2018 – Albireo Pharma 1Q Loss/Shr 15c; 15/03/2018 – Albireo Pharma 2017 Loss/Shr $3.15; 09/05/2018 – Federated Investors Buys New 2.6% Position in Albireo Pharma; 17/05/2018 – ALBIREO PHARMA INC ALBO.O : WEDBUSH RAISES TARGET PRICE TO $69 FROM $63; 17/05/2018 – Albireo Provides First Quarter 2018 Business Update; 27/03/2018 – Albireo Pharma Presenting at Conference Tomorrow; 15/03/2018 ALBIREO PHARMA INC – ABOUT $200 MLN CURRENT CASH BALANCE EXPECTED TO BE SUFFICIENT TO FUND OPERATIONS INTO 2021; 03/04/2018 – Albireo Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4); 14/05/2018 – Fidelity & Research Buys New 5.3% Position in Albireo Pharma
More notable recent Albireo Pharma, Inc. (NASDAQ:ALBO) news were published by: Nasdaq.com which released: “FDA Grants Rare Pediatric Disease Designation to A4250; Albireo Eligible to Apply for Priority Review Voucher” on June 12, 2018, also Streetinsider.com with their article: “Albireo Pharma (ALBO) Says FDA Granted it Rare Pediatric Disease Designation to A4250” published on June 12, 2018, Seekingalpha.com published: “Albireo Pharma nabs Rare Pediatric Disease tag for A4250 for rare liver disorder; shares up 7% premarket” on June 12, 2018. More interesting news about Albireo Pharma, Inc. (NASDAQ:ALBO) were released by: Globenewswire.com and their article: “Albireo to Present at Jefferies 2018 Global Healthcare Conference” published on May 29, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More” with publication date: May 17, 2018.
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal disorders in the United States. The company has market cap of $382.26 million. The Company’s lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase II clinical trial for treating progressive familial intrahepatic cholestasis and primary biliary cholangitis. It currently has negative earnings. The companyÂ’s clinical-stage product candidates comprise Elobixibat, an orally administered IBAT inhibitor, which is in Phase III clinical trial for the treatment of chronic constipation and other GI diseases; and A3384, a development stage product to treat bile acid malabsorption.
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle Mucus Penetrating Particles technology. The company has market cap of $337.00 million. The companyÂ’s product candidates include KPI-121 1.0%, which has completed Phase 3 clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-121 0.25% that is in Phase 3 clinical trials for the temporary relief of the signs and symptoms of dry eye disease. It currently has negative earnings. It also develops KPI-285, a receptor kinase inhibitor, which is in preclinical studies for the treatment of various retinal diseases.